California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Heidelberg, Germany, February 28, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Florian Fischer, CFO, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 10:40 a.m. (ET) in Boston.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the respective conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
